Skip to content
OpenCapital
Get started

Ocular Therapeutix OCUL Debt Issuance Cost Amortization

Debt Issuance Cost Amortization at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$3M-40.0%
HRO
HarrowHROW
$451K-64.6%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$159K+14.4%
PBH
Prestige Consumer HealthcarePBH
$456K+4.1%
TG Therapeutics logo
TG TherapeuticsTGTX
$285K-6.3%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
$1M-9.1%

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's debt issuance cost amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's debt issuance cost amortization?
Ocular Therapeutix (OCUL) reported debt issuance cost amortization of $1.38M in Q1 2026.
How has Ocular Therapeutix's debt issuance cost amortization changed year-over-year?
Ocular Therapeutix's debt issuance cost amortization decreased by 3.8% year-over-year, from $1.44M to $1.38M.
What is the long-term trend for Ocular Therapeutix's debt issuance cost amortization?
Over 4 years (2021 to 2025), Ocular Therapeutix's debt issuance cost amortization has grown at a -7.4% compound annual growth rate (CAGR), from $4.63M to $3.4M.
What does debt issuance cost amortization mean?
Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).